Evaluation of ALK gene status in primary lung adenocarcinoma and matched metastases

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1146-

  Rossi, Antonio ^a   Galetta, Domenico ^b   Bottiglieri, Luca ^c   Stufano, Viviana ^c   Barberis, Massimo ^c  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR; GEMCITABINE; K RAS PROTEIN; PEMETREXED;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; EML4 ALK FUSION GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LETTER; LUNG ADENOCARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PERITONEUM METASTASIS; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; THORACOSCOPY; TREATMENT RESPONSE;

EID: 79958100197     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31821528fc     Document Type: Letter

References (3)

1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566. (Pubitemid 47206930)
3. Antoniu SA. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for advanced disease? Expert Opin Ther Targets 2011;15:351-353.